alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Office of the Citizenship and Immigration Services Ombudsman

How to Request Case Assistance from the Ombudsman: 

Scope of Assistance Provided 

Helping Individuals and Employers Resolve Problems with USCIS 

Before asking the Ombudsman for help with an application or petition, try to resolve the issue with USCIS by: 

• Submitting a request through your myUSC/S account;

• Submitting an e-Request with USCIS online at https://egov.uscis.gov/e-Request; or

• Contacting USCIS for assistance at 1-800-375-5283.

Option 

1 Option Submit 

case assistance 

an online 

available 

request for 

on 2 the Ombudsman's website at 

Download a printable case 

assistance form (Form DHS-7001) 

from the Ombudsman's website 

www.dhs.gov/cisombudsman. www.dhs.gov/cisombudsman. 

0 SUBMIT A SIGNED CASE ASSISTANCE FORM

AND SUPPORTING DOCUMENTATION BY: 0 RECOMMENDED PROCESS

Email: 

cisombudsman@hq.dhs.gov 

Fax: 

(202) 357-0042

Request Assistance 0 AFTER RECEIVING A REQUEST FOR

CASE ASSISTANCE, THE OMBUDSMAN: Mail: 

If you are unable to resolve your 

issue with USCIS, you may 

request assistance from the 

Ombudsman. Certain types of 

requests involving refugees, 

asylees, victims of violence, 

trafficking, and other crimes 

must be submitted with a 

handwritten signature for 

consent purposes. This can be 

done using Option 1 to the right 

and uploading a signed Form 

DHS-7001 to the online request 

for case assistance. 

Office of the Citizenship and 

Immigration Services Ombudsman 

STEP 1 U.S. Department of 

Provides a case Homeland Security 

submission number to 

confirm receipt. 

Attention: Case Assistance 

Mail Stop 0180 

Washington, DC 20528-0180 

STEP2 Individuals submitting a request 

from outside the United States 

cannot use the online request 

form and must submit a hard copy 

case assistance request form. 

Reviews the request for completeness, 

including signatures and a Form G-28, 

Notice of Entry of Appearance as 

Attorney or Accredited Representative, 

if submitted by a legal representative. 

STEP4 

Contacts USCIS field offices, 

service centers, asylum offices, 

or other USCIS offices to help 

resolve difficulties the individual 

or employer is encountering. 

STEP3 

Assesses the current status of the 

application or petition, reviews relevant 

laws and policies, and determines how 

the Ombudsman can help. 

STEPS 

Communicates the actions 

taken to help.
§ 520.1860 Pradofloxacin. ( a ) *Specifications.* Each milliliter of suspension contains 25 milligrams (mg) pradofloxacin.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cats* — ( 1 ) *Amount.* Administer 3.4 mg/lb (7.5 mg/kg) body weight once daily for 7 consecutive days.
( 2 ) *Indications for use.* For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of *Pasteurella multocida, Streptococcus canis,* *Staphylococcus aureus, Staphylococcus felis,* and *Staphylococcus pseudintermedius.*
( 3 ) *Limitations.* Federal law prohibits the extralabel use of this drug in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[77 FR 76863, Dec. 31, 2012, as amended at 79 FR 28827, May 20, 2014; 86 FR 14819, Mar. 19, 2021]
§ 56.110 Expedited review procedures for certain kinds of research involving no more than minimal risk, and for minor changes in approved research. ( a ) The Food and Drug Administration has established, and published in the Federal Register, a list of categories of research that may be reviewed by the IRB through an expedited review procedure. The list will be amended, as appropriate, through periodic republication in the Federal Register.
( b ) An IRB may use the expedited review procedure to review either or both of the following: ( 1 ) Some or all of the research appearing on the list and found by the reviewer(s) to involve no more than minimal risk,
( 2 ) minor changes in previously approved research during the period (of 1 year or less) for which approval is authorized. Under an expedited review procedure, the review may be carried out by the IRB chairperson or by one or more experienced reviewers designated by the IRB chairperson from among the members of the IRB. In reviewing the research, the reviewers may exercise all of the authorities of the IRB except that the reviewers may not disapprove the research. A research activity may be disapproved only after review in accordance with the nonexpedited review procedure set forth in § 56.108(c).
( c ) Each IRB which uses an expedited review procedure shall adopt a method for keeping all members advised of research proposals which have been approved under the procedure.
( d ) The Food and Drug Administration may restrict, suspend, or terminate an institution's or IRB's use of the expedited review procedure when necessary to protect the rights or welfare of subjects.
[46 FR 8975, Jan. 27, 1981, as amended at 56 FR 28029, June 18, 1991]
OLEM/OSRTI

Washington, DC 20460

NATIONAL PRIORITIES LIST (NPL) 

***Proposed Site*** April 2016 

DORADO GROUND WATER 

CONTAMINATION

Dorado, Puerto Rico

 Site Location:

The Dorado Ground Water Contamination site is located in a mixed residential/commercial/industrial area in the 

municipality of Dorado, Puerto Rico. Dorado is situated along the northern coast and to the west of San Juan.

 Site History:

The site consists of an area of ground water containing organic based solvents, but the contamination cannot be clearly 

attributed to any specific source or sources. Ground water wells are the primary suppliers to the two active public water 

supply systems, Maguayo and Dorado Urbano, which are operated in Dorado by Puerto Rico Aqueduct and Sewer 

Authority (PRASA). Wells in the Maguayo and Dorado Urbano systems have been contaminated since the 1980s. Some 

wells have been closed either temporarily or permanently due to the presence of these solvents. 

Ground water is contaminated with organic based solvents, primarily tetrachloroethylene (PCE) and trichloroethylene 

(TCE), which are commonly used in commercial and industrial operations such as dry cleaning and metal degreasing. 

 Site Contamination/Contaminants:

 Potential Impacts on Surrounding Community/Environment: 

The contaminated wells withdraw water from the upper aquifer of the North Coast Limestone Aquifer System. The upper 

aquifer is the principal source of fresh ground water in Dorado and historically has been the principal source of public and 

industrial water use in the region. The ground water contamination affects drinking water supply wells in the Maguayo and 

Dorado Urbano public water systems, which are the source of drinking water for more than 67,000 people. 

 Response Activities (to date):

Some wells have been closed temporarily or permanently due to contamination. The Super Aqueduct is used to supplement 

the water supply to the extent possible.

 Need for NPL Listing:

The commonwealth of Puerto Rico referred this site to the EPA. Other federal and state cleanup programs were evaluated, 

but are not viable at this time. The EPA received a letter of support for placing this site on the NPL from the 

commonwealth of Puerto Rico. 

[The description of the site (release) is based on information available at the time the site was evaluated with the HRS. The description may 

change as additional information is gathered on the sources and extent of contamination. See 56 FR 5600, February 11, 1991, or 

subsequent FR notices.] 

For more information about the hazardous substances identified in this narrative summary, including general information regarding the effects of exposure to these 

substances on human health, please see the Agency for Toxic Substances and Disease Registry (ATSDR) ToxFAQs. ATSDR ToxFAQs can be found on the Internet 

at http://www.atsdr.cdc.gov/toxfaqs/index.asp or by telephone at 1-888-42-ATSDR or 1-888-422-8737.
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

MUSHTAQ AHMED MIAN and YASMIN MUSHTAQ MIAN , Appellant s ,

v.

HER R ON BAY COMMUNITY ASSOCIATION INC.
, Appellee

.

No. 4D 17

- 3147

[ June 28, 2018 ]

Appeal from the Circuit Court for the Seventeenth Judicial Circuit, Broward County ; Martin J. Bidwill , Judge; L.T. Case No. 15

- 011836 CACE

05

.

Gregory M. Ochalek, P.L.L.C., Miami Gardens, for appellants.

Shelley J. Murray of Straley & Otto, P

. A

. , Fort Lauderdale, for appellee.

P ER C URIAM

.

Affirmed.

G ERBER
, C.J., G ROSS and C IKLIN
, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
Exhibit 32.2

CERTIFICATION OF CHIEF ACCOUNTING OFFICER

Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350)

The undersigned, Kevin G. Wills, Executive Vice President and
Chief Financial Officer of Saks Incorporated (the Company), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Companys Quarterly Report on Form 10-Q for the quarter
ended October 31, 2009 (the Report).

The undersigned hereby certifies that:



|1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|-- | ---------------------------------------------------------------------------------------------------------------------



|2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------

IN WITNESS WHEREOF, the undersigned has executed this certification as of the 4th day of December, 2009.



|                                                                   
|-------------------------------------------------------------------
|/s/ Kevin G. Wills                                                 
|Kevin G. Wills Executive
Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Saks
Incorporated and will be retained by Saks Incorporated and furnished to the Securities and Exchange Commission or its staff upon request.
§ 522.144 Arsenamide. ( a ) *Specifications.* Each milliliter of solution contains 10.0 milligrams arsenamide sodium.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer 0.1 milliliter (mL) per pound of body weight (1.0 mL for every 10 pounds) by intravenous injection twice a day for 2 days.
( 2 ) *Indications for use.* For the treatment and prevention of canine heartworm disease caused by *Dirofilaria immitis.*
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16184, Mar. 25, 2014, as amended at 84 FR 39183, Aug. 9, 2019]
Editorial Note on Part 341
Editorial Note: Nomenclature changes to part 341 appear at 69 FR 13717, Mar. 24, 2004.

§ 341.70 Labeling of OTC drug products containing ingredients that are used for treating concurrent symptoms (in either a single-ingredient or combination drug product). The statements of identity, indications, warnings, and directions for use, respectively, applicable to each ingredient in the product may be combined to eliminate duplicative words or phrases so that the resulting information is clear and understandable. ( a ) *For products containing diphenhydramine citrate and diphenhydramine hydrochloride identified in § 341.14(a)(5) and (a)(6) .* The labeling of the product contains the established name of the drug, if any, and identifies the product as an “antihistamine/cough suppressant” or “antihistamine/antitussive (cough suppressant).” The indications shall be combined from §§ 341.72(b) and 341.74(b). The warnings shall be combined from §§ 341.72(c)(1), (c)(2), (c)(4), and (c)(6) and 341.74(c)(1), (c)(2), (c)(3), and (c)(4). Alternatively, all of the warnings in § 341.74(c) shall be used. The directions for OTC labeling shall follow §§ 341.74(d)(1)(iv) or (d)(1)(v), as applicable. The directions for professional labeling shall follow § 341.90(j) or (k), as applicable.
( b ) *For products containing menthol identified in §§ 341.14(b)(2) and 356.12(f) of this chapter .* The product contains 5 to 10 milligrams menthol. The labeling of the product contains the established name of the drug, if any, and identifies the product as a “cough suppressant/oral anesthetic” or “antitussive (cough suppressant)/oral anesthetic.” The indications shall be combined from § 341.74(b) and part 356 of this chapter. The warnings shall be combined from § 341.74(c)(1), (c)(2), and (c)(3) and part 356 of this chapter. The directions shall be: “Directions [in bold type] [bullet][1] adults and children 2 years and over: dissolve lozenge slowly in the mouth. Repeat every 2 hours as needed or as directed by a doctor. [bullet] children under 2 years of age: ask a doctor”.
[61 FR 15703, Apr. 9, 1996, as amended at 67 FR 78170, Dec. 23, 2002; 68 FR 17881, Apr. 14, 2003] Footnotes -
341.70
[1] See § 201.66(b)(4) of this chapter for definition of bullet symbol.
§ 556.330 Hygromycin B. ( a ) [Reserved]
( b ) *Tolerances.* The tolerances for hygromycin B are: ( 1 ) *Chickens.* Edible tissues: Zero.
( 2 ) *Swine.* Edible tissues: Zero.
( c ) *Related conditions of use.* See § 558.274 of this chapter.
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM AVITAR'S
QUARTERLY REPORT FOR THE QUARTER ENDED JUNE 30, 1999 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<MULTIPLIER> 1


<S>                              <C>
<PERIOD-TYPE>                          9-MOS
<FISCAL-YEAR-END>                SEP-30-1999
<PERIOD-START>                    OCT-1-1998
<PERIOD-END>                     JUN-30-1999
<CASH>                             1,234,527
<SECURITIES>                               0
<RECEIVABLES>                        245,543
<ALLOWANCES>                               0
<INVENTORY>                          185,777
<CURRENT-ASSETS>                   1,870,029
<PP&E>                             1,044,311
<DEPRECIATION>                       884,576
<TOTAL-ASSETS>                     2,046,764
<CURRENT-LIABILITIES>              1,488,222
<BONDS>                                    0
<PREFERRED-MANDATORY>                      0
<PREFERRED>                           18,515
<COMMON>                             214,167
<OTHER-SE>                           304,229
<TOTAL-LIABILITY-AND-EQUITY>       2,046,764
<SALES>                            1,586,621
<TOTAL-REVENUES>                   1,586,621
<CGS>                              1,334,407
<TOTAL-COSTS>                      3,262,327
<OTHER-EXPENSES>                     (93,174)
<LOSS-PROVISION>                           0
<INTEREST-EXPENSE>                   117,800
<INCOME-PRETAX>                   (1,700,332)
<INCOME-TAX>                               0
<INCOME-CONTINUING>               (1,700,332)
<DISCONTINUED>                             0
<EXTRAORDINARY>                            0
<CHANGES>                                  0
<NET-INCOME>                      (1,700,332)
<EPS-BASIC>                           (.12)
<EPS-DILUTED>                           (.12)



</TABLE>
EXHIBIT 32.2




CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the accompanying Quarterly Report on Form 10-Q of Southwall Technologies Inc. (the “Company”), for the quarter ended June 30, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mallorie Burak, the Principal Financial Officer of the Company, hereby
certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




August 14, 2009
By:
/s/ Mallorie BurakMallorie BurakChief Accounting Officer




A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.





In accordance with Item 601 of Regulation S-K, this certification is being “furnished” as Exhibit 32.2 to the Company's quarterly report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
§ 582.5936 Vitamin A palmitate. ( a ) *Product.* Vitamin A palmitate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Exhibit 10.7

 

[Company Letterhead]

 

March 29, 2017

 

Karen Thornton

Hand Delivered

 

Re: Updated Retention Bonus Offer

 

Dear Karen,

 

On December 16, 2016, you received a letter awarding you a retention bonus in recognition of your contributions and your support of our cost containment initiatives during the oil and gas economic downturn. This letter is a replacement to update the terms and conditions of the outstanding retention bonus, canceling you prior retention offer.

 

	
Milestone
    	
 
    	
Amount Paid
    
	
 
    	
 
    	
 
    
	
Later of July 1, 2017
    (payable on July 14, 2017 pay date)
 or
 Achievement   of monthly Adjusted EBITDA averaging $15M for 3 consecutive months
    	
 
    	
25% of Salary (as of 8/8/15)
    


 

As before, to be eligible for the retention bonus payments, you must be an active full-time employee of the Company on the applicable bonus payment date. If you are terminated for cause, you will not be eligible for the retention bonus payable thereafter. If you are terminated without cause or the Company completes a sale of a majority of its equity or substantially all of its assets, the retention bonus will be paid to you in the next available pay cycle. You must sign FTSI’s Separation and Release Agreement in order to receive this payment. If you voluntarily terminate your employment with FTSI before three months of continuous employment following each payment, you agree to repay that payment in full within 20 business days following the termination of employment.

 

Sincerely,

 

	
/s/ Mike Doss
    	
 
    
	
 
    	
 
    
	
Michael Doss
    	
 
    
	
Chief Executive Officer
    	
 
    


 

I agree to and accept the terms set forth in this letter.

 

	
/s/ Karen Thornton
    	
 
    	
3/29/17
    
	
Employee Signature
    	
Date
Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not *

be published and is not precedent except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 08-50464

Summary Calendar

UNITED STATES OF AMERICA

Plaintiff-Appellee

v.

ROLAND SAMANIEGO

Defendant-Appellant

Appeal from the United States District Court

for the Western District of Texas

USDC No. 5:04-CR-340-1

Before JONES, Chief Judge, and DENNIS and HAYNES, Circuit Judges.

PER CURIAM:*

Roland Samaniego, federal prisoner #43425-180, appeals the district

court’s denial of his 18 U.S.C. § 3582(c)(2) motion to reduce his sentence imposed

following his guilty plea conviction for conspiracy to possess with intent to

distribute cocaine. Samaniego argues that he is entitled to have his sentence

reduced in light of Amendment 709 to the Sentencing Guidelines. He argues

that Amendment 709 modified U.S.S.G. §§ 4A1.1 and 4A1.2, and, thus he is

entitled to have his criminal history score recalculated. 

United States Court of Appeals

Fifth Circuit

F I L E D

June 2, 2009

Charles R. Fulbruge III

Clerk
No. 08-50464

2

Pursuant to § 3582(c)(2), a defendant may have his sentence modified if

he was sentenced to a term of imprisonment based upon a sentencing range that

subsequently was lowered by the Sentencing Commission. The district court

may grant a reduction if consistent with the applicable policy statements issued

by the Sentencing Commission. § 3582(c)(2); United States v. Gonzalez-Balderas,

105 F.3d 981, 982 (5th Cir. 1997). Section 3582(c)(2) applies only to retroactive

guidelines amendments, as set forth in the guidelines policy statement. See

U.S.S.G. § 1B1.10(a); United States v. Shaw, 30 F.3d 26, 28-29 (5th Cir. 1994).

Unless an amendment is listed in § 1B1.10(c), a reduction based on the

amendment under § 3582(c) is not consistent with the policy statement of

§ 1B1.10. See § 1B1.10, comment. (n.1(A)). Amendment 709 is not listed as an

amendment covered by the policy statement in § 1B1.10(c). See § 1B1.10(c) (May

2008). Therefore, under the plain language of § 3582(c), a district court does not

abuse its discretion by denying a reduction in a sentence based on Amendment

709. See § 1B1.10, comment. (n.1(A)). Samaniego has failed to show that the

district court erred in concluding that Amendment 709 did not apply

retroactively and could not be used to support a motion under § 3582(c).

Samaniego concedes that the district court was correct in its determination

that he is not entitled to relief under Amendment 706 because he was convicted

for a powder cocaine offense and not a crack cocaine offense. See United States

v. Burns, 526 F.3d 852, 861 (5th Cir. 2008). Thus, the district court did not

abuse its discretion in denying Samaniego’s § 3582(c) motion. See Shaw, 30 F.3d

at 28. Accordingly, the judgment of the district court is AFFIRMED.
Opinion issued February 14, 2014

In The 

## Court of Appeals For The 

## First District of Texas

———————————— NO. 01
- 14
- 00134
- CV

——————————— IN RE ADRIENE L. SIBLEY , Relator
Original Proceeding on Petition for Writ of Mandamus

MEMORANDUM OPINION On February 12, 2014, relator, Adriene L. Sibley, petition ed this Court for a writ of mandamus challenging a temporary restraining order entered by the trial

court. * A temporary injunction hearing is scheduled for February 18, 2014, at 9:00 a.m. The temporary restraining order will expire by its terms on February 20, 2014.

* The underlying case is Seminole Pipeline Company LLC v. Adriene Sibley a/k/a Adriene Gail Lewis, Reginald Timothy Rossow, Sr., Winston James Rossow, Johnel Lewis, Donyll Dwayne Lewis, Dushay Demitric Lewis, and Lamont Deshawn Lewis , cause number C150979, pending in the County Court at Law No. 3 of Brazoria County, Texas, the Honorable Jeremy Warren presiding.2

The petition for a writ of mandamus is denied

. See Walker v. Packer , 827 S.W.2d 833, 840 (Tex. 1992) (“mandam us will not issue where there is an adequate remedy by appeal” ) ; T EX
. R. C IV
. P. 680 (temporary restraining order granted without notice “shall expire by its terms” within 14 days); T EX
. C IV
. P RAC
. & R EM
. C ODE § 51.014(a)(4) (authorizing interlocutory appe al from order granting temporary injunction). Relator’s “Motion for Emergency Stay and Motion for Review of Bond for Temporary Restraining Order,” filed in conjunction with her petition for writ of mandamus, is denied

. PER CURIAM
Panel consists of Chief Ju stice Radack and Justices Massengale and Huddle.